Targeting Protein Kinases for Cancer Therapy (eBook)
720 Seiten
John Wiley & Sons (Verlag)
978-1-118-21077-2 (ISBN)
therapy
Research has shown that protein kinases can instigate the
formation and spread of cancer when they transmit faulty signals
inside cells. Because of this fact, pharmaceutical scientists have
targeted kinases for intensive study, and have been working to
develop medicinal roadblocks to sever their malignant means of
communication.
Complete with full-color presentations, Targeting Protein
Kinases for Cancer Therapy defines the structural features of
protein kinases and examines their cellular functions. Combining
kinase biology with chemistry and pharmacology applications, this
book enlists emerging data to drive the discovery of new
cancer-fighting drugs. Valuable information includes:
* Comprehensive overviews of the major kinase families involved in
oncology, integrating protein structure and function, and providing
important tools to assist pharmaceutical researchers to understand
and work in this dynamic area of cancer drug research
* Focus on small molecule inhibitors as well as other therapeutic
modalities
* Discussion of kinase inhibitors that have entered clinical
trials for the treatment of cancer, with an emphasis on molecules
that have progressed to late stage clinical trials and, in a few
cases, to market
Providing a platform for further study, this important work
reviews both the successes and challenges of kinase inhibitor
therapy, and provides insight into future directions in the war
against cancer.
DAVID J. MATTHEWS is Executive Director of Oncology Discovery at Exelixis, where he is responsible for cancer drug discovery. For more than fifteen years, Dr. Matthews has been involved in drug discovery projects in industry, with particular focus on small molecule inhibitors. He has twenty scientific publications and multiple patents to his credit. MARY E. GERRITSEN is Vice President of Molecular and Cellular Pharmacology at Exelixis, where she is in charge of cell-based screening in preclinical research and of biomarker studies for clinical development compounds in Phase I and II studies. Her prior industry experience includes positions at Genentech, Bayer and Millennium Pharmaceuticals. She has authored more than one hundred peer-reviewed articles and twenty-six book chapters and is an inventor on forty-two issued patents.
"The comprehensive coverage makes the book highly recommendable for beginners and expert researchers in oncology and should be present on their shelves." (ChemMedChem, November 2010)
"This excellent book is a comprehensive review of protein kinases
in the context of their roles in human cancer. ... [It] is an
excellent resource for scientists involved in selecting potential
drug targets and optimization of compounds that are likely to be
effective. The involvement of protein kinases in cancer, and
strategies for selecting drug targets is thoughtfully discussed,
and protein structures, domains and sites of regulation are
described in depth and in ways that are easy to follow and
understand. Individual kinases are described from the biological
perspective and in the context of efforts to target them, often
with case studies to illustrate specific points in exquisite
detail. Understanding these proteins at this level of detail is
essential to understand how they can be targeted and what we can
expect to observe in the clinic. Following description of the
kinases themselves and their function and regulation in signaling
pathways, and cell cycle control, the second half of this book
describes kinase inhibitors and experience gained from analyzing
these compounds in vitro and in vivo. The final chapter addresses
challenges and future directions, including issues relating to
combinational therapy and systems biology. These big issues
complete the comprehensive tour of the world of kinases in the
context of cancer, from molecular details of drug-protein
interactions, through biology to clinical application. Considering
the success so far in targeting these enzymes in the clinic, and
the level of investment currently being made to developing new
kinase inhibitors for cancer therapy, there is no doubt that this
outstanding book will be a valuable asset to the large community of
chemists, biologists and clinicians involved in developing the next
generation of therapies."
--Frank McCormick, Director, UCSF Helen Diller Family
Comprehensive Cancer Center
Erscheint lt. Verlag | 20.9.2011 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Naturwissenschaften ► Chemie | |
Schlagworte | Biowissenschaften • Chemie • Chemistry • Drug Discovery & Development • Krebstherapie • Life Sciences • Medical Science • Medizin • Oncology & Radiotherapy • Onkologie • Onkologie u. Strahlentherapie • Proteine u. Makromoleküle • Proteine u. Makromoleküle • Proteinkinase • Proteins & Macromolecules • Wirkstoffforschung u. -entwicklung |
ISBN-10 | 1-118-21077-8 / 1118210778 |
ISBN-13 | 978-1-118-21077-2 / 9781118210772 |
Haben Sie eine Frage zum Produkt? |
Größe: 6,5 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich